Impact Factor 2.129 | CiteScore 2.40
More on impact ›

Perspective ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Psychol. | doi: 10.3389/fpsyg.2019.02338

Dose-response matters! – A perspective on the exercise prescription in exercise-cognition research

  • 1German Center for Neurodegenerative Diseases (DZNE), Germany
  • 2Medical School Hamburg, Germany

In general, it is well-recognized that both acute physical exercises and regular physical training influence brain plasticity and cognitive functions positively. However, growing evidence shows that the same physical exercises induce very heterogeneous outcomes across individuals. In an attempt to better understand this interindividual heterogeneity in response to acute and regular physical exercising, most research, so far, has focused on non-modifiable factors such as sex and different genotypes, while relatively little attention has been paid to exercise prescription as a modifiable factor. With an adapted exercise prescription dosage can be made comparable across individuals, a procedure which is necessary to better understand the dose-response relationship in exercise-cognition research. This improved understanding of dose-response relationships could help to design more efficient physical training approaches against, for instance, cognitive decline.

Keywords: physical activity, Cognition, Personalized training, personalized medicine, neuroplasticity, Neuroprotection

Received: 29 Apr 2019; Accepted: 01 Oct 2019.

Copyright: © 2019 Herold, Müller, Gronwald and Mueller. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Mr. Fabian Herold, German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany,